Published in Clin Exp Rheumatol on August 22, 1994
CD8 lymphocytes in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol (1994) 1.73
Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41
"Lymphokines": non-antibody mediators of cellular immunity generated by lymphocyte activation. Nature (1969) 6.42
Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J (1978) 4.29
Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum (1992) 3.92
An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol (1982) 3.05
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum (1992) 2.68
The sensitivity and specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol (1994) 2.61
HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A (1989) 2.60
A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide. J Immunol (1990) 2.55
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med (1980) 2.52
Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum (1992) 2.31
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol (1984) 2.17
A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism. Lancet (1978) 2.15
Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis (1993) 2.01
Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol (1984) 1.95
A novel in vivo murine model of cartilage regeneration. Age and strain-dependent outcome after joint surface injury. Osteoarthritis Cartilage (2008) 1.87
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis (1989) 1.68
IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Scand J Rheumatol (1983) 1.67
B lymphocyte alloantigens in the study of the genetic basis of rheumatoid arthritis. Ann Rheum Dis (1977) 1.65
Analysis of T cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies. Ann Rheum Dis (1983) 1.64
The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol (2001) 1.62
Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol (1993) 1.57
Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study. Ann Rheum Dis (1987) 1.54
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 1.49
Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum (2005) 1.49
Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford) (2003) 1.47
Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis (1994) 1.44
The cycling of combination antirheumatic drug therapy in rheumatoid arthritis. Br J Rheumatol (1990) 1.41
Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol (1990) 1.38
Influence of pregnancy on disease activity in a patient with palindromic rheumatism. J Rheumatol (1992) 1.38
ELISA assays for IgM and IgG rheumatoid factors. J Immunol Methods (1982) 1.37
Selective migration of the human helper-inducer memory T cell subset: confirmation by in vivo cellular kinetic studies. Eur J Immunol (1991) 1.34
Circadian variation in disease activity in rheumatoid arthritis. Br Med J (Clin Res Ed) (1982) 1.30
Human pregnancy serum inhibits interleukin-2 production. Clin Exp Immunol (1984) 1.29
HLA-DRw4 and rheumatoid arthritis. Lancet (1979) 1.29
Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Hum Immunol (1991) 1.27
Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Ann Rheum Dis (1983) 1.23
Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis. Eur J Immunol (1994) 1.22
Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun (2000) 1.21
Disease activity and pregnancy associated alpha 2-glycoprotein in rheumatoid arthritis during pregnancy. Br Med J (Clin Res Ed) (1983) 1.20
Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol (1990) 1.20
Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter's disease. Arthritis Rheum (1991) 1.19
The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) (2002) 1.19
Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis (1983) 1.19
Activated T lymphocytes of the synovial membrane in rheumatoid arthritis and other arthropathies. Scand J Immunol (1985) 1.19
Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology (1988) 1.15
Sequence analysis of HLA-DR4B1 subtypes: additional first domain variability is detected by oligonucleotide hybridization and nucleotide sequencing. Hum Immunol (1990) 1.14
In vivo analysis of disease modifying drug therapy activity in rheumatoid arthritis by sequential immunohistological analysis of synovial membrane interleukin 1 beta. J Rheumatol (1994) 1.13
Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum (2002) 1.12
Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol (1991) 1.12
Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: evidence for "frustrated" activation. J Rheumatol (1987) 1.11
Neuroendocrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives. Semin Arthritis Rheum (1999) 1.11
Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis? Clin Exp Immunol (2011) 1.10
Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum (2001) 1.09
Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am (2001) 1.09
Response of rheumatoid-synovial-fluid lymphocytes to non-specific mitogens. Lancet (1973) 1.07
Lymphocyte studies in rheumatoid arthritis. III. A comparative study of the responses of peripheral blood and synovial fluid lymphocytes to phytomitogens. Scand J Rheumatol (1979) 1.07
A combined immunohistological and histochemical analysis of lymphocyte and macrophage subpopulations in the rheumatoid nodule. Clin Exp Immunol (1984) 1.05
Detection of immune complexes in serum of patients with ankylosing spondylitis. Ann Rheum Dis (1978) 1.05
Cytokines and the chronic inflammation of rheumatic disease. II. The presence of interleukin-2 in synovial fluids. Clin Exp Immunol (1984) 1.04
Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis (1981) 1.03
Histocompatibility antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol (1983) 1.02
Clotrimazole in rheumatoid arthritis. Ann Rheum Dis (1980) 1.02
Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect. Ann Rheum Dis (1973) 1.02
HLA-DR4 restricted lymphocyte proliferation to a Mycobacterium tuberculosis extract in rheumatoid arthritis and healthy subjects. J Immunol (1988) 1.02
Serum and secretory IgA immune response to Klebsiella pneumoniae in ankylosing spondylitis. Clin Rheumatol (1983) 1.01
Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) (2000) 1.00
Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum (1995) 1.00
An improved method for sacro-iliac joint imaging: a study of normal subjects, patients with sacro-iliitis and patients with low back pain. Clin Radiol (1981) 0.99
CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol (2000) 0.99
Simultaneous ligation of CD5 and CD28 on resting T lymphocytes induces T cell activation in the absence of T cell receptor/CD3 occupancy. J Immunol (1993) 0.99
Changes in immune function in patients with rheumatoid arthritis following treatment with sodium aurothiomalate. Ann Rheum Dis (1981) 0.99
Does rheumatoid arthritis have a clinicopathological spectrum similar to that of leprosy? Ann Rheum Dis (1982) 0.98
Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) (2002) 0.98
Carcinoembryonic antigen in rheumatoid arthritis. Lancet (1974) 0.98
Atopy and rheumatoid arthritis. Clin Allergy (1985) 0.98
Abnormal helper-inducer/suppressor-inducer T-cell subset distribution and T-cell activation status are common to all types of chronic synovitis. Scand J Immunol (1988) 0.98
Modulation of cellular annexin I in human leukocytes infiltrating DTH skin reactions. J Leukoc Biol (1999) 0.97
Abnormal lymphocyte reactivity to self-major histocompatibility antigens in rheumatoid arthritis. J Rheumatol (1987) 0.97
Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol (2001) 0.97
Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol (1993) 0.97
Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum (1996) 0.97
Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor. Ann Rheum Dis (1980) 0.97
Functional assay of cytotoxic lymphocytes involved in antibody-mediated cytotoxicity in normal and rheumatoid subjects. Ann Rheum Dis (1977) 0.97
Deficient sulphoxidation status and D-penicillamine toxicity. Lancet (1983) 0.96